Compare Ishares Msci Spain ETF (EWP) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Novo Nordisk A/S — how do they compare? Ishares Msci Spain ETF trades at $59.23, while Novo Nordisk A/S trades at $51.44 (market cap $222.24B). The key difference: Novo Nordisk A/S pays a 3.56% dividend while Ishares Msci Spain ETF pays none, and Ishares Msci Spain ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| EWP | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $60.28 | $71.70 |
52-Week Low | $43.90 | $35.29 |
Market Cap | — | $222.24B |
Enterprise Value | — | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP trades at $59.26, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend, supported by strong moving average alignment, while oscillators remain neutral. The stock exhibits tight support at $59 and resistance at $60. A dividend of $0.92 per share is scheduled for payment on June 18, 2026.
The outlook for EWP is cautiously optimistic due to bullish technicals and upcoming dividend returns. Key risks include European economic sensitivity to energy price volatility and potential interest rate impacts. Investors should monitor ECB policy decisions and regional economic performance for directional cues.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
